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Abstract
Context—Sex steroid hormone receptor (SHR) dynamics are well-documented in human
endometrium but have not been comprehensively studied in Fallopian tube (FT).
Objective—To compare expression patterns and hormonal regulation of SHR in FT with that
described in endometrium, and determine whether SHR expression is altered in FT of women with
ectopic pregnancy (EP).
Design—Tissue analysis and culture.
Patients or Other Participants—Women undergoing surgery for benign gynaecological
conditions (n=14) and EP (n=6).
Interventions—Q-RT-PCR and immunohistochemistry were used to determine SHR mRNA
expression and protein localization, respectively. SHR levels were measured in tubal explant
cultures stimulated with estrogen and progestogen.
Results—ERα and ERβ mRNAs were constitutively expressed in FT during the menstrual cycle.
PR-AB and PR-B mRNAs were decreased in mid-luteal compared to follicular phase. ERα, PR-
AB and PR-B mRNAs were downregulated in human FT in vitro by treatment with progestogen.
ERα, ERβ1, ERβ2, PR and AR proteins localised to cell nuclei of epithelium, stroma and smooth
muscle of non-pregnant FT. In FT from women with EP, PR-B mRNA was decreased when
compared to mid-luteal FT, and ERα protein was not detected.
Conclusions—SHR expression in FT is different from that observed in endometrium recovered
at similar stages of the menstrual cycle and expression in FT from women with EP is also altered
compared with normal FT. These data are an important benchmark for furthering understanding of
normal human FT physiology, transcriptional changes in FT in response to progesterone, and
disorders of FT function, such as EP.
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Introduction
The female reproductive system is exposed to fluctuating levels of sex steroids, including
estrogen and progesterone during the normal menstrual cycle. A number of studies have
investigated the expression patterns of the estrogen (ER), progesterone (PR) and androgen
(AR) receptors in the human endometrium and documented both cell-specific patterns of
expression as well as hormone dependent changes during the menstrual cycle (reviewed in
(1)). However, the expression of sex steroid hormone receptors has yet to be
comprehensively studied in the normal human Fallopian tube or in the context of tubal
pathologies, such as ectopic pregnancy.
Sex steroid-regulated changes in Fallopian tube gene expression and function likely
contribute to successful embryo tubal transport and implantation. The aim of this study was
to compare expression patterns and regulation of sex steroid hormone receptors in the
Fallopian tube with that described in endometrium. We also hypothesised that their
expression pattern would be altered in Fallopian tube of women with ectopic pregnancy.
Sex steroid hormone receptors belong to a superfamily of genes that function as ligand-
activated transcription factors (2). They have a conserved arrangement of functional
domains, the most important of which are the DNA-binding domain containing two zinc
fingers and a ligand binding domain found towards the C-terminus of the protein.
Two ER genes have been identified: ERα (ESR1; (3)) and ERβ (ESR2; (4)). Splice variant
isoforms of the latter are expressed in a variety of human tissues (5, 6). ERα and ERβ
exhibit different functional properties in vitro and show distinct patterns of gene regulation
(7, 8). At present, although expression of ERβ1 and ERβ2 has been detected in normal
endometrium, their roles are still unclear (1). However, it has been suggested that both ERβ1
and ERβ2 may have an impact on ERα-mediated gene expression (9).
Expression of ER in the human Fallopian tube was first described prior to the discovery of
ERβ (10, 11). ER was immunolocalised to epithelial cells in the ampullary and fimbrial
sections of the Fallopian tube and was reputed to increase throughout the follicular phase
before reaching a plateau in the luteal phase (11). The antibody used in the studies was a
mouse monoclonal antibody raised against purified calf uterine estrogen receptor.
Expression of ERβ was recently documented in the human Fallopian tube using a rabbit
polyclonal antibody raised against the amino-terminus of ERβ but levels were not assessed
at different phases of the menstrual cycle (12). Expression of ERα or ERβ has not been
examined in Fallopian tube from women with ectopic pregnancy.
Human PR is expressed as two isoforms, PR-A (94 kDa) and PR-B (116 kDa) both encoded
by a single gene (13). PR-A is a truncated form of PR-B and lacks 164 amino acids from the
N-terminus. Although both PR-A and PR-B bind progesterone, selective physiological roles
for the two isoforms of PR have been documented (14). Generally, PR-B is transcriptionally
the more active of the two isoforms (15). Furthermore, PR-A can act as a dominant repressor
of PR-B-dependent activation of progestin-sensitive reporter genes, and likewise inhibits the
transcriptional activity of receptors for androgens, glucocorticoids and mineralocorticoids
(16).
Expression of PR in the Fallopian tube was first characterised in the early 1990s (10, 11).
Using antibodies that crossreact with both PR-A and PR-B, these studies showed that
immunoexpression of epithelial PR expression was most intense in the follicular phase but
that it was not detected in the late luteal phase (11). A general reduction in PR protein
expression has also been reported in Fallopian tube from women with ectopic pregnancy
using immunoscoring and a mouse monoclonal antibody (IgG1 clone PR88) raised against
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purified human progesterone receptor (17). More recently, expression of mRNAs specific
for PR-A and B have been studied in non-pregnant Fallopian tube. Regional tubal
expression of PR-A and PR-B mRNA was shown to vary, but again this was not studied in
relation to cycle phase (18).
Human AR is encoded by a single copy gene on the X chromosome and in vivo it binds
either testosterone or 5α-dihydrotestosterone (19). AR expression has been documented in
the non-pregnant human Fallopian tube by Western blot analysis using rabbit monoclonal
antibodies which recognise full length AR proteins (20), but no quantitative or topographical
studies have, to our knowledge, been performed.
In the current study, we performed a detailed analysis of expression of ERα, ERβ1, ERβ2,
PR-A, PR-B and AR in the human Fallopian tube across the menstrual cycle and compared
this with expression in Fallopian tubes of women with ectopic pregnancy. These in vivo
observations were complemented and extended using an in vitro model.
Methods
Tissue collection
Ethical approval for this study was obtained from Lothian Research Ethics Committee (04/
S1103/20). All women were aged 18-45 years. Written and informed consent was obtained
from all patients before sample collection. Fallopian tube biopsies (all from ampullary
region unless stated), endometrial biopsies (for histological dating) and sera (for
measurement of circulating estradiol and progesterone concentrations for endocrine staging)
were collected from women with regular menstrual cycles (21-35 days) undergoing
gynecological procedures for benign conditions who had no previous history of ectopic
pregnancy and had not taken any hormonal preparations in the three months prior to surgery
(n=14; see Table 1). None of the gynaecological conditions listed have been reported to date
to affect sex steroid hormone receptor expression in the endometrium so it was assumed that
this would also be the case in the Fallopian tube. Fallopian tube was also obtained from
women undergoing surgical management of tubal ectopic pregnancy (n=6; see Table 2).
None of the women undergoing surgical management of ectopic pregnancy presented
acutely with haemodynamic shock, and all required serial serum beta-HCG and ultrasound
monitoring prior to diagnosis. Part of the Fallopian tube was (a) immersed in RNAlater™
(Ambion, Texas, USA) at 4°C overnight then flash frozen at −70°C; part of the Fallopian
tube and the endometrial biopsies were (b) fixed in 10% neutral buffered formalin overnight
at 4°C, stored in 70% ethanol, and wax embedded; or (c) collected into PBS for tissue
culture. The endometrial biopsies underwent haematoxylin and eosin staining and dating by
an expert histopathologist.
Quantitative RT-PCR
RNA was extracted from cells/tissues as detailed in the manufacturer's protocol (Qiagen,
RNeasy mini kits). All samples were treated with DNase I (Qiagen) in order to remove any
contaminating genomic DNA. Complementary DNA was synthesised from 400ng of total
RNA in 20μl reaction volumes containing: 1×RT buffer, magnesium chloride, dNTPs,
random hexamers, RNase inhibitor and Multiscribe reverse transcriptase (Applied
Biosystems, Cheshire, UK). Reactions were incubated at 25°C for 20 min, 42°C for 60 min
then 95°C for 5 min. Negative controls contained either template RNA but no reverse
transcriptase (RT negative) or no template RNA (RT water). PCR reaction mixtures
contained Taqman 2x Master-mix (1x; Applied Biosystems), forward and reverse primers
(300nM; Eurogentec) and probe (200nM; Eurogentec) for ERα, ERβ, PR-AB, PR-B or AR,
and forward and reverse primers and probe for ribosomal 18S (all 50nM; Applied
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Biosystems). ERα, ERβ, PR-AB, PR-B and AR primers and probes were designed using
Primer Express software and their sequences are shown in Table 3. Ribosomal 18S was used
as a housekeeping gene. Negative control (water in place of cDNA) samples were included
in each PCR run along with the RT negative and RT H2O control samples described above.
All samples were analysed in triplicate using the 2−ΔΔCt method. PCR reactions were run on
an ABI 7900 Sequence Detection System (Perkin-Elmer Applied Biosystems, USA).
Immunohistochemistry
Immunohistochemical localisation of ERα, ERβ1, ERβ2, PR and AR was performed on
Fallopian tube sections using biotinylated secondary antibodies and peroxidase conjugated
detection systems. Immunoreactivity was detected using the chromagen 3,3′-
diaminobenzidine (DAB). In brief, tissue sections were dewaxed in xylene and rehydrated in
descending grades of alcohol. Sections were subjected to antigen retrieval as described in
Table 4 and then non-specific activity was blocked sequentially with 3% hydrogen peroxide
(Sigma-Aldrich), avidin and biotin, and protein blocks. Sections were incubated overnight at
4°C with antibodies specific to either: ERα, ERβ1, ERβ2, PR and AR (see Table 4).
Sections were subsequently incubated with biotinylated secondary antibodies (Vector
Laboratories, Peterborough, UK) and HRP complex (ABC-Elite, Vector Laboratories) or
Streptavidin (Dako, Cambridge, UK), then immunoreactivity detected using DAB (Vector
Laboratories). Counterstaining was then performed with Harris' haemotoxylin and mounted
in Pertex (Cellpath Technologies, Hemel Hempstead, UK).
Tissue culture
Tubal explant cultures were performed as previously described (21) using surgical tissue
from the ampullary region (unless indicated otherwise) of non-pregnant Fallopian tubes
collected across the menstrual cycle. Fallopian tube biopsies were cut into small pieces (2-3
mm), placed in a 12-well dish with the luminal epithelial surface facing upwards and
cultured in RPMI containing 10% charcoal-stripped fetal-bovine serum at 37°C in 5% CO2.
After 24 hours in culture, the tissues (n=5) were exposed to ethanol (as a control), and either
estradiol (E2) (10nM), medroxyprogesterone acetate (MPA) (1μM), or a combination of
10nM E2 and 1μM MPA, for a further 24 hours. Following treatments quantitative RT-PCR
for ERα, ERβ1, ERβ2, PR-AB, PR-B and AR was performed as above.
Statistical analysis
Data were logarithmically transformed prior to statistical analysis. Significant difference
was determined by one-way ANOVA and Tukey's posthoc analysis.
Results
Expression of PR-AB and PR-B mRNAs is significantly diminished in the mid-luteal phase
of the menstrual cycle
Expression of ERα and ERβ2 mRNAs did not change according to phase of menstrual cycle
(Fig. 1A and C). There was a trend for expression of ERβ1 mRNA to be higher in the mid-
luteal compared to the follicular phase of the menstrual cycle although this was not
statistically significant (Fig. 1B). Expression of PR-AB and PR-B mRNAs was significantly
reduced in the mid-luteal phase compared to the follicular phase of the menstrual cycle
(p<0.05, Fig. 1D and E). Tubal AR mRNA expression showed a similar, but non-significant
trend (Fig. 1D).
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Progestogen downregulates expression of ERα, PR-AB and PR-B mRNAs in the human
Fallopian tube in vitro
Incubation of tubal explants for 24h in the presence of E2 alone had no impact on total
concentrations of any of the SHR mRNAs (Fig. 2). Likewise there was no change in
expression of ERβ1, ERβ2 or AR mRNAs after incubation with MPA alone or E2 plus
MPA (Fig. 2B, C and F, respectively). In contrast expression of ERα, PR-AB and PR-B
mRNAs was significantly downregulated after incubation with MPA alone or MPA plus E2
for 24 hours (p<0.01) (Fig. 2A, D and E, respectively).
Expression of PR-B mRNA expression is significantly diminished in the Fallopian tube of
women with ectopic pregnancy
Total concentrations of ERα, ERβ1, ERβ2, PR-AB, and AR mRNAs were not statistically
different in the Fallopian tube of women with ectopic pregnancy and those recovered during
the luteal phase of the cycle (Fig. 3A, B, C and D, respectively). However, expression of
PR-B mRNA was significantly reduced in the Fallopian tubes of women with ectopic
pregnancy (p<0.05) (Fig. 3E) compared to those from the mid-luteal phase.
ERα protein was not detected in the Fallopian tube of women with ectopic pregnancy
ERα protein was immunolocalised to the nuclei of the epithelial cells, stroma and smooth
muscle of non-pregnant Fallopian tube from all phases of the menstrual cycle (representative
images in Figs. 4A and 5A) but expression was not detected in women with ectopic
pregnancy (Fig. 5B). ERβ1, ERβ2, PR and AR were all detected in all the nuclei within the
epithelial layer and within approximately 50% of those within the stromal and smooth
muscle layers in all the Fallopian tube biopsies (representative images in Fig. 4B-F and Fig.
5C-F). One full-length Fallopian tube from the mid-luteal phase was examined for regional
expression of SHR proteins. Similar patterns of nuclear staining were detected in epithelial,
stromal and smooth muscle cells using antibodies specific for ERα, ERβ1, ERβ2, PR and
AR in sections from the isthmic, ampullary and infundibulo-fimbrial regions.
Discussion
To our knowledge, this is the first comprehensive description of the patterns of expression of
ERα, ERβ1, ERβ2, PR-A, PR-B and AR in the human Fallopian tube at different stages of
the menstrual cycle. We have also used an in vitro model system to investigate the impact of
acute exposure to E2 and/or MPA on expression of sex steroid hormone receptors in this
tissue. In addition, we report on differences in sex steroid hormone receptor expression in
Fallopian tube from women with ectopic pregnancy compared to non-pregnant Fallopian
tube.
We demonstrate that total expression of PR-AB and PR-B mRNAs are significantly reduced
in non-pregnant Fallopian tubes recovered during the mid-luteal phase of the cycle as
compared with those obtained during during the follicular phase. Surprisingly, expression of
ERα mRNA in the Fallopian tube remains constant across the menstrual cycle i.e. ERα is
not downregulated in the mid luteal phase, when the tissue is exposed to peak levels of
circulating progesterone.
Our data extend the findings of a study that examined expression of PR-B mRNA in the
Fallopian tube during the mid-luteal phase but did not compare expression to other phases of
the menstrual cycle (22). In the context of Fallopian tube function, particularly the ciliary
and tubal smooth muscle activity essential for successful embryo-tubal transport and
subsequent implantation in the uterus, the downregulation of PR is important (23).
Progesterone is reported to have an inhibitory action on ciliary and tubal smooth muscle
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activity because high progesterone levels in the luteal phase coincide with a reduced
frequency of contractions and ciliary activity in vitro (24, 25). Information on the regulation
of specific genes by progesterone in the oviduct is limited, largely due to limited access to
human Fallopian tube cells. This contrasts with the data on the endometrium where as many
as 571 genes (representing 131 biochemical pathways) have been shown to be progesterone-
regulated (26).
However, our data suggest that expression of SHR in the Fallopian tube do not simply
mirror the changes seen in the endometrium. For example, in vivo expression of PR, and
ERα, is reduced in endometrium in the mid-secretory phase of the menstrual cycle under the
influence of progesterone and seems to be closely connected to the onset of endometrial
receptivity (27). We therefore used an in vitro system to confirm and extend the findings
that we observed in the non-pregnant Fallopian tube during the menstrual cycle by
examining the impact of E2 and MPA on sex steroid hormone receptor expression. In these
studies, we demonstrated downregulation of expression of PR-AB, PR-B and ERα mRNAs
after treatment of Fallopian tube explants with MPA alone, and in combination with E2.
There are many in vivo and in vitro studies which report results consistent with the
downregulation in expression of PR-A, PR-B and ERα mRNAs after incubation with
progestagens (reviewed in (1)). For example, several studies have shown that administration
of the PR antagonist, mifepristone, to patients in the early secretory phase of the menstrual
cycle prevents downregulation of PR and ERα expression in the mid secretory phase (28,
29). Progestogens attenuate the actions of E2 in endometrium (30) and both PR-A and PR-B
have been shown to inhibit ER transcriptional activity via a ligand-dependent mechanism in
rat uterine cells (31). A more recent study has reported that PR-B overexpression in breast
cancer cell lines reduces expression of ERα (32). This effect is dependent on recruitment of
a corepressor transcriptional complex to a progesterone response element half site in the
ERα promoter (32). In vitro studies have also shown that PR is downregulated by
progestogen although this effect is cell-type dependent. In the T47D breast cancer cell line
and in endometrial epithelial cells expression of both PR-A and PR-B is suppressed by
progestogen treatment (10nM ORG 2058 and 0.2μm MPA, respectively) (33, 34). In
contrast, PR-A and PR-B are upregulated in endometrial stromal cells by progestogen
treatment (0.2μm MPA) (34). The differences seen in our in vivo compared to our in vitro
findings in the Fallopian tube suggest that additional local factors may be involved in the
regulation of ERα expression.
We also report reduced expression of PR-B mRNA in Fallopian tube from women with
ectopic pregnancy compared to non-pregnant Fallopian tube from the mid-luteal phase of
the menstrual cycle. It is not possible to collect Fallopian tube from women with intra-
uterine pregnancies and so Fallopian tube collected from the mid luteal phase, when
circulating progesterone levels are raised, provides the most appropriate control. Our
findings support those of an earlier immunohistochemical study that could not detect PR
protein expression in the Fallopian tube of women with ectopic pregnancy (17). It may also
offer an explanation for the absence of adequate tubal decidualization observed with this
condition (35). Mice deficient in PR fail to mount a decidual response and a recent study in
humans has shown that PRs regulate distinct gene networks and cellular functions in
decidualizing endometrium (36, 37).
In addition, we were unable to detect expression of ERα protein by immunohistochemistry
in the Fallopian tube from women with ectopic pregnancy which was surprising as there was
no difference in the total amount of ERα mRNA. Although this may reflect the limitations
of our immunohistochemical approach, receptor protein was readily detected in tubes
obtained during the normal cycle. Notably, ERα gene polymorphisms have been associated
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with female infertility (38), and ERα has been shown to serve as a dominant regulator in
Fallopian tube development in the rat (39). Furthermore, a recent study in mice has
identified a molecular mechanism for ERα-mediated tubal protein synthesis and secretion
that appears to be important for successful embryonic development (40). Further studies are
required to determine whether ERα plays a critical role in Fallopian tube physiology and to
establish whether reduced translation or enhanced degradation may contribute to reduced
expression of protein.
In summary, we report that there are variations in sex steroid hormone receptor expression
in the non-pregnant human Fallopian tube during the menstrual cycle, that there is in vitro
regulation of some SHRs in the Fallopian tube by E2 and MPA, and identified differences in
expression in Fallopian tubes from women with ectopic pregnancy compared to the non-
pregnant Fallopian tube. Sex steroid receptor dynamics and responsiveness to estrogen and
progestogen have been demonstrated in many studies in the endometrium (reviewed in (1)).
However, studies in the human Fallopian tube have been limited to date. Our data is
therefore an important benchmark for furthering understanding of normal human Fallopian
tube physiology, transcriptional changes in the Fallopian tube in response to progesterone,
and the aetiology of disorders of Fallopian tube function, such as ectopic pregnancy.
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Fig. 1. Sex steroid hormone receptor mRNA expression in the human Fallopian tube across the
menstrual cycle (follicular, mid-luteal and menstrual phases)
Expression of ERα (A), ERβ1 (B), ERβ2 (C), and AR (F) did not change according to phase
of menstrual cycle. PR-AB (D) and PR-B (E) mRNA expression were significantly
diminished in the luteal phase compared to expression in the follicular phase of the cycle
(p<0.05).
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Fig. 2. Tubal explant culture with sex steroids
Stimulation of tubal explants (n=5) with estradiol (E2) (10nM) and medroxyprogesterone
acetate (MPA) (1μM) showed no change in ERβ1 (B), ERβ2 (C) and AR (F) mRNA
expression after 24 hours. ERα (A), PRA-AB (D) and PR-B (E) mRNA expression was
significantly downregulated after treatment with medroxyprogesterone acetate, and in
combination with estradiol (p<0.01).
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Fig. 3. Sex steroid hormone receptor mRNA expression in the human Fallopian of women with
ectopic pregnancy
ERα (A), ERβ1 (B), ERβ2 (C), PR-AB (D) and AR (F). PR-B mRNA expression was
significantly lower in the Fallopian tube of women with ectopic pregnancy compared to
expression in the non-pregnant Fallopian tube in the mid-luteal phase of the cycle (p<0.05).
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Fig. 4. Representative images of the immunolocalisation of sex steroid hormone receptor protein
in the human Fallopian tube across the menstrual cycle
A) ERα expression in the follicular phase. B) ERβ1 expression in the mid-luteal phase. C)
ERβ2 expression in the follicular phase. D) PR expression in the follicular phase. E) PR
expression in the mid-luteal phase. F) AR expression in the follicular phase. Sex steroid
hormone receptor protein was localised to the nuclei of all the epithelial cells, approximately
50% of the stromal cells and the smooth muscle in all biopsies of non-pregnant Fallopian
tube at all stages of the menstrual cycle.
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Fig. 5. Representative images of the immunolocalisation of sex steroid hormone receptor protein
in Fallopian tube from women with ectopic pregnancy
A) ERα expression in the menstrual phase (control). B) ERα expression in women with
ectopic pregnancy. ERβ1 (C), ERβ2 (D), PR (E), and AR (F) expression in women with
ectopic pregnancy. There was no evidence of ERα protein expression in Fallopian tube
obtained from women with ectopic pregnancy (compare A with B). However, ERβ1, ERβ2,
PR, and AR immunolocalisation in Fallopian tube from women with ectopic pregnancy was
similar to that observed for non-pregnant Fallopian tube.
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Table 2
Demographics of Fallopian tube biopsies for women undergoing surgery for ectopic pregnancy.
Gestation (days) hCG (IU/L) Prog (nmol/L)
1 58 15956 67.43
2 50 487 39.21
3 59 2056 24.58
4 53 1854 63.07
5 52 2425 61.68
6 56 225 20.36
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